SRAD vs. DOCS, WIX, YOU, CNIC, SLP, NET, GVP, ARBB, CYN, and INSE
Should you be buying Stelrad Group stock or one of its competitors? The main competitors of Stelrad Group include Dr. Martens (DOCS), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Sylvania Platinum (SLP), Netcall (NET), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), CQS Natural Resources Growth and Income (CYN), and Inspired (INSE). These companies are all part of the "computer software" industry.
Stelrad Group vs. Its Competitors
Stelrad Group (LON:SRAD) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.
Stelrad Group pays an annual dividend of GBX 8 per share and has a dividend yield of 4.9%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.9%. Stelrad Group pays out 68.7% of its earnings in the form of a dividend. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Stelrad Group has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
35.5% of Stelrad Group shares are owned by institutional investors. Comparatively, 69.5% of Dr. Martens shares are owned by institutional investors. 64.4% of Stelrad Group shares are owned by company insiders. Comparatively, 4.4% of Dr. Martens shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 28.08% beat Dr. Martens' return on equity.
Dr. Martens has a consensus target price of GBX 6,000, indicating a potential upside of 7,641.94%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Stelrad Group.
In the previous week, Dr. Martens had 2 more articles in the media than Stelrad Group. MarketBeat recorded 2 mentions for Dr. Martens and 0 mentions for Stelrad Group. Dr. Martens' average media sentiment score of 0.62 beat Stelrad Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.
Dr. Martens has higher revenue and earnings than Stelrad Group. Dr. Martens is trading at a lower price-to-earnings ratio than Stelrad Group, indicating that it is currently the more affordable of the two stocks.
Summary
Dr. Martens beats Stelrad Group on 11 of the 17 factors compared between the two stocks.
Get Stelrad Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRAD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stelrad Group Competitors List
Related Companies and Tools
This page (LON:SRAD) was last updated on 7/3/2025 by MarketBeat.com Staff
Free SRAD Stock Alerts